Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

847 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-15

Study Completion Date

2021-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Latin America.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

NCT05505175

Breast Cancer Breast Carcinoma

COMPLETED

Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

NCT04937660

Metastatic Breast Cancer

COMPLETED

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

NCT04394247

Breast Cancer

COMPLETED

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

NCT04460911

Breast Cancer

COMPLETED

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481

Breast Cancer

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast Cancer Patients

HR + /HER2- Advanced/Metastatic Breast Cancer patients in Latin America

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Oncologist or gynecologist.
* Responsible for treating ≥4-10 (depending on country) ABC/MBC patients who meet the eligibility criteria.
* Agrees to participate in the study and complete the case report forms (CRFs) within the data collection period.

* HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease.
* Received palbociclib as a first line therapy.
* No prior or current enrolment in an interventional clinical trial for ABC/MBC.
* Minimum of six months of follow up data since palbociclib initiation.

Exclusion Criteria

* Qualified less than 2 years ago or more than 35 years ago.
* Participated in observational research for ABC/MBC in the last 3 months.
* Have not prescribed either palbociclib plus fulvestrant or palbociclib plus aromatase inhibitor as first line therapy.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No